IXHL
Incannex Healthcare, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · AU
$2.53
+0.94%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$2.58
From 52W high−82.39%
Volume29294.00
Market cap$31.72M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$2.58
From 52W high
−82.39%
Volume
29294.00
Market cap
$31.72M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
1.6x
P/E (TTM)
—
RSI (14)
39.9
MomentumView details →
1D Return
+0.94%
YTD Return
−75.70%
SummaryUpdated Jun 1, 2026
Incannex Healthcare Limited (ASX:IXHL) is an Australian pharmaceutical company that develops medicinal cannabinoid products for various medical conditions. Founded in 2001 and originally known as Impression Healthcare Limited, the company rebranded to Incannex Healthcare in June 2020 to reflect its focus on cannabinoid-based therapeutics. The company went public on the Australian Securities Exchange in March 2022. Incannex is currently in the clinical development phase, with multiple drug candidates in various stages of trials targeting conditions such as obstructive sleep apnea, traumatic brain injury, and inflammatory diseases.
Similar companies
Latest newsMore news →